Loading
Loading
Your feedback directly shapes Sporos.
Sign in to track your feedback history
Real federal data (a held corpus snapshot, not a live feed), really analyzed — this run was generated 2026-07-02 and replays instantly.
All artifactsCorpus footprint · true records per corpus
Assessment
Eli Lilly is a top-tier federal policy actor: 300 lobbying filings on record across 12+ retained firms, sustained in-house spend running $1.4–1.8M per quarter, and a $65B revenue / $21B net income financial profile that makes it one of the most consequential pharmaceutical companies before Congress and regulators. Its sharpest immediate exposure is a triple FDA warning letter cluster issued September 2025, all directed to CEO David Ricks personally, concerning promotional violations for tirzepatide (Zepbound/Mounjaro) — its highest-growth franchise and the center of gravity for its current market capitalization.
Takeaway: Lilly operates one of the most elaborately staffed pharmaceutical lobbying programs in Washington — 300 filings on record, with in-house quarterly spend of $1.4M–$1.8M supplemented by a rotating bench of 12+ retained firms active continuously from at least 2008 through Q1 2024, signaling a permanent, resource-intensive federal affairs posture rather than episodic engagement.
In-house filings show $1.4M spent in Q1 2019 [4] and $1.8M in Q4 2019 [5] — these single-quarter figures alone exceed what most companies spend annually on lobbying. The retained network active in 2019 includes Venn Strategies ($50K/Q) [1], Tarplin Downs & Young ($80K/Q) [2], Guidepost Strategies ($66K/Q) [3], Monument Advocacy ($50K/Q) [7], and BGR Government Affairs ($50K/Q each in Q1 and Q3 2019) [6][8]. The 2024 filings confirm the bench has been maintained or expanded: Todd Strategy Group [11], Monument Advocacy [12], The Simmons & Russell Group [13], Ferox Strategies [14], Williams & Jensen [15], and Venn Strategies [16] all reported Q1 2024 activity. Invariant LLC and The OB-C Group appear as far back as Q1 2008 [9][10], indicating continuity of multi-firm strategy over nearly two decades.
Assessment: The co-occurrence data — Tarplin D&Y (31 filings), Venn Strategies (31), Monument (29), Tiber Creek (25), Simmons & Russell (24), Ferox (21) — confirms these are not one-off engagements but deep, recurring relationships. Lilly's lobbying architecture is calibrated to cover multiple congressional committees, party alignments, and issue tracks simultaneously (drug pricing, Medicare negotiation, FDA regulation, patent/IP, GLP-1 coverage policy). For a compliance or buy-side reader: Lilly is not reacting to Washington; it is attempting to shape it.
Takeaway: Lilly's financials reflect a company in rapid, GLP-1-driven revenue expansion — $65B in revenue, $21B net income, and $112B in total assets for FY 2025 — with active institutional ownership churn (34 13D/G filings on record) and regular insider activity by the CEO and CFO, all consistent with a high-visibility, high-liquidity large-cap under sustained institutional scrutiny.
XBRL-sourced FY 2025 10-K figures: Revenues $65B [20], Net Income $21B [21], Total Assets $112B [22]. This represents a dramatic scale-up from the 2022 10-Q period [27][28], consistent with tirzepatide launch trajectory. Eight-K filings span 2024–2025 [23][24][25][26], indicating a regular cadence of material event disclosures. Proxy filings run 2022–2024 [39–46], covering executive compensation and governance disclosures across the period of Lilly's largest market cap appreciation.
The 13D/G cluster (34 filings on record) includes SC 13D (activist/blockholder) filings from late 2022 [47][48] and multiple 13G/A passive-holder amendments from institutional names in early 2022 [49–54] — the 13D filings warrant closer review as they suggest a named party took an active ownership position. SEC correspondence filings in 2022 [29] and 2023 [30] indicate SEC Staff review of Lilly's disclosure practices in at least two review cycles.
Insider transactions (42 on record) show CEO David Ricks filing Forms 4 in February 2025 [58][59][61], August 2024 [60], and February 2026 [62]; CFO Jamere Jackson filed in November 2025 [55], August 2025 [56], and November 2024 [57]. The frequency and recency of CEO/CFO Form 4 filings is elevated and worth monitoring for Rule 10b5-1 plan disclosures and timing relative to drug approval announcements.
Takeaway: All three FDA enforcement records are warning letters issued on a single date — September 9, 2025 — addressed personally to CEO David Ricks, all targeting tirzepatide promotional materials, representing a concentrated and brand-critical enforcement action against Lilly's most commercially important drug franchise.
Warning Letter 1 (NDA 217806 and 215866, MA 974 and 832) concerns a direct-to-consumer video titled "An Oprah Special: Shame…" — CDER found the promotional communication violated FDA promotional standards for both Zepbound and Mounjaro simultaneously [17]. Warning Letter 2 (NDA 217806, MA 831) concerns a separate DTC online video featuring Lilly representatives [18]. Warning Letter 3 (NDA 217806, MA 824) concerns a third DTC online video of an interview featuring Lilly representatives [19].
Assessment: Three simultaneous warning letters on the same day, all directed to the CEO by name, all concerning tirzepatide DTC promotional content, is an aggressive enforcement posture from CDER. FDA warning letters for promotional violations typically require a corrective action response and can precede injunctive action or import alerts if not remediated promptly. For Lilly, the stakes are compounded: tirzepatide is its principal revenue growth driver. The Oprah-branded video [17] suggests Lilly's marketing strategy leaned heavily on celebrity/media amplification — a tactic that historically draws FDA scrutiny for implied superiority claims, omission of risk information, or misleading context. These are leads that require verification of Lilly's formal response and any subsequent FDA follow-up.
No records retrieved from OFAC SDN or HHS-OIG LEIE screens as of their ~May 2026 snapshot. Absence here is not evidence of no exposure — it means no matched record in these specific screen sources at this snapshot date, not a certified-clean determination.
No records retrieved. The USAspending corpus is a partial backfill (contracts capped at 50K rows, grants at 2.5K rows); counts are a floor. Lilly has documented federal revenue streams — Medicare Part B/D drug reimbursement, VA formulary contracts, DoD procurement — that would not necessarily appear in this screen at current coverage levels. Absence here should be treated as a data gap, not absence of federal revenue dependency.
Takeaway: The 8 Federal Register records are a mix of directly Lilly-relevant product actions and incidental name-match notices — the directly relevant ones concern tirzepatide's commercial context, a patent extension determination for Kisunla (donanemab), a controlled substances scheduling for Lilly's lasmiditan (Reyvow), and a Strattera market withdrawal determination.
Directly Lilly-linked:
Incidental/non-Lilly records: The Quantum Energy Partners FTC petition [65], the Enbridge FTC petition [67], the Pfizer NDA withdrawal notice [68], and the SEC MD&A final rule [69] do not appear to directly involve Lilly and are likely name-proximity artifacts.
Bottom line: Four things matter here, in priority order:
1. FDA Warning Letters — Immediate Action Item. Three simultaneous CDER warning letters (September 9, 2025) directed to CEO Ricks covering tirzepatide (Zepbound/Mounjaro) promotional violations [17][18][19] are the single most time-sensitive federal exposure. Tirzepatide is Lilly's primary growth engine at $65B total revenue [20]. Failure to remediate promptly can escalate to injunctive relief or criminal referral. Verify Lilly's formal FDA response and whether corrective advertising has been required.
2. Lobbying Scale and Drug Pricing Exposure. With 300 filings on record and a multi-firm retained apparatus running continuously through at least Q1 2024, Lilly's federal affairs machine is calibrated primarily around pharmaceutical pricing and reimbursement policy — the IRA's Medicare drug price negotiation provisions hit Lilly's portfolio directly. Watch for lobbying activity targeting tirzepatide's potential selection as a Medicare negotiation target post-2025.
3. Insider Transaction Pattern at Inflection. CEO Ricks and CFO Jackson have filed Forms 4 at high frequency through 2025–2026 [55–62] during the period of maximum tirzepatide-driven stock appreciation and simultaneous FDA enforcement action. Timing relative to warning letter receipt and any 10b5-1 plan structures warrants scrutiny.
4. Kisunla/Donanemab IP Runway. The patent extension determination notice [66] signals active IP lifecycle management for Lilly's Alzheimer's franchise. Kisunla's market trajectory and exclusivity window are a secondary but growing revenue story; regulatory and reimbursement decisions (CMS coverage) on amyloid-targeting Alzheimer's drugs remain unsettled and will drive federal exposure in this product line.
*Coverage note: Retrieved records are a capped sample; true corpus totals are 300 lobbying filings, 169 SEC filing sections, 142 XBRL facts, 46 SEC filings, 42 insider transactions, 34 13D/G filings, 15 proxy statements, 13 LDA Senate filings, 8 regulatory records, 3 FDA enforcement letters, and 1 bill — all figures per Sporos footprint counts.*
Verification · 1 claim to verify · 11/12 grounded to evidence (8 to the exact cited source)
Screen sources: OFAC SDN + HHS-OIG LEIE (snapshots as of ~May 2026). No match = no linked record, not a certified-clean screen.
No records retrieved for this surface.
Partial corpus: the USAspending backfill is paused (contracts 50K rows held of a much larger set; grants 2.5K). Counts are a floor, not the total.
No records retrieved for this surface.
Entity network · co-occurring across the corpus
Generated 7/2/2026, 12:15:56 PM · 70 primary sources · citations resolve to the publisher’s record wherever the publisher offers a direct link.
Build this dossier for a company you cover — not just Eli Lilly — talk to us. We’re onboarding design partners; live runs are set up per team.
Back to all artifacts